Galectin Therapeutics (GALT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for January 23, 2025, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by January 22, 2025.

Voting matters and shareholder proposals

• Election of eleven directors is on the agenda, with the board recommending a vote for all nominees.

• Ratification of Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.

• Provision to transact other business that may properly come before the meeting or any adjournments.

Board of directors and corporate governance

• Eleven director nominees are listed, including individuals with diverse backgrounds in science, medicine, and business.